In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, explores the key factors driving the increasing number of partnerships between telehealth and ...

Approval was based on positive results from the Phase III balance study, where Tryngolza demonstrated a notable placebo-adjusted triglyceride reduction at 12 months. The FDA has approved Ionis ...

Talking about ethics isn’t exactly exciting. Leaders don’t usually jump at the chance to emphasize following rules or exceeding standards—it’s much more appealing to focus on growth than on problems.

Accelerated approval was based on promising results from the ongoing Phase III BREAKWATER trial. The FDA has granted accelerated approval to Pfizer’s Braftovi (encorafenib) in combination with ...

In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome. Pharmaceutical Executive recently brought together a group of experts to discuss the ...

These professionals in the healthcare marketing sector have been chosen by their peers for making big moves and taking on larger roles. The pharmaceutical industry is undergoing a transformative era, ...

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses the recent DEA extensions of telehealth for controlled substances and new treatment modalities ...

Artificial intelligence (AI) is set to revolutionize the pharmaceutical industry, offering unprecedented efficiencies in product development and manufacturing processes. By manipulating and processing ...

New technology is making it easier for more companies to embrace telehealth, which in turn is providing more opportunities for pharma companies to interact with HCPs and patients. Peter Ax, founder ...

GLP-1s are the most discussed drug of 2024. While they were initially developed to treat diabetes, the drug’s ability to help with weight loss has made them extremely popular. So much so that in 2023, ...

The molecule is an investigational pre-clinical oral GLP-1 receptor agonist. Merck entered into an agreement with Hansoh Pharma in which the former company will obtain the global license agreement for ...

Amid the end of a national GLP-1 shortage, the FDA will now require all compounding, distributing, or dispensing of compounded tirzepatide injections to end within 90 days. The FDA has updated its ...